GlassScriptPhysician profile
Hung-I Liao
NPI 1346623550
$13,657.56
in general payments reported to CMS, 2019-2025
29 companies · $3,990 in 2025
The $3,990 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $1,307 · 2023: $2,765 · 2024: $5,475 · 2025: $3,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,820 · Education: $3,134 · Travel and Lodging: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,819.77 |
| Education | $3,133.99 |
| Travel and Lodging | $275.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,405.99 | 2024-2025 | |
| Glaxosmithkline, LLC. | $2,895.10 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,445.05 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Amgen INC. | $978.73 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $730.95 | 2022-2025 | Ofev, Stiolto Respimat, Jascayd |
| Mylan Specialty L.P. | $710.79 | 2022-2024 | Yupelri |
| Genzyme Corporation | $656.89 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $537.69 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $444.63 | 2022-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $284.51 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $274.34 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $246.10 | 2025 | Yupelri |
| Abbvie INC. | $236.19 | 2022-2025 | |
| United Therapeutics Corporation | $157.29 | 2023-2025 | Tyvaso, Tyvaso |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $90.12 | 2022-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $76.40 | 2023-2025 | Veklury |
| Paratek Pharmaceuticals, INC. | $64.38 | 2023 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $60.69 | 2023-2024 | |
| Philips North America LLC | $52.93 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Caris Mpi, INC. | $34.63 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $29.84 | 2023 | Xolair |
| Actelion Pharmaceuticals US, INC. | $28.07 | 2024 | Uptravi, Opsumit |
| Electromed, INC. | $27.19 | 2025 | Smartvest |
| Merck Sharp & Dohme LLC | $24.22 | 2023 | |
| Janssen Pharmaceuticals, INC | $18.12 | 2024 | Xarelto |
| Inogen, INC. | $17.80 | 2022 | |
| Inspire Medical Systems, INC. | $14.89 | 2024 | Inspire |
| Resmed Corp | $14.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung-I Liao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.